Dr. Michael R. Shafique
- Medical Oncologist
- Pleural Mesothelioma Specialist
- Expertise:
-
Clinical Trials
Immunotherapy - Speciality:
-
Medical Oncology
- Gender:
-
Male
- Language:
-
English
- Expertise:
-
Clinical Trials
Immunotherapy - Speciality:
-
Medical Oncology
- Gender:
-
Male
- Language:
-
English
Primary Location
Moffitt Discovery and Innovation Center at Speros16370 Wilton Way, Land O Lakes, FL 34638
DirectionsAbout Dr. Michael R. Shafique
Dr. Michael R. Shafique’s practice centers on thoracic oncology, with experience treating pleural mesothelioma and several other cancers of the chest. He also treats lung cancer, neuroendocrine tumors, Pancoast tumors and thymoma.
Most of Dr. Shafique’s clinical work involves lung cancer, but he also treats people with other diagnoses through early-phase clinical trials. His research interests include immunotherapy, drug development and new ways to bring investigational treatments into patient care.
Specialties of Dr. Shafique
- Clinical trials
- Immunotherapy
- Lung cancer
- Medical oncology
- Neuroendocrine tumors
- Pancoast tumors
- Pleural mesothelioma
- Thymoma
Dr. Shafique’s Medical Education and Experience
- Moffitt Cancer Center, Medical Oncologist
- Moffitt Cancer Center, Medical Director
- Moffitt Cancer Center, Principal Investigator on industry-sponsored and cooperative-group clinical trials
- University of South Florida/Moffitt Cancer Center (Hematology and Medical Oncology Fellowship)
- Duke University Medical Center (Internal Medicine Residency)
- University of Virginia School of Medicine (M.D.)
Awards and Certifications
- American Board of Internal Medicine, Hematology
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- Tampa Magazine Top Doctor in Medical Oncology, 2025
Dr. Shafique’s Research and Clinical Trials
Dr. Shafique is a principal investigator for industry-sponsored and cooperative-group studies, particularly in lung cancer. He’s part of Moffitt’s Immuno-Oncology Program and Lung Cancer Center of Excellence. He serves in a medical leadership role supporting the expansion of interventional clinical trials across Moffitt’s ambulatory clinic locations. He works with researchers at Moffitt and other cancer centers to study how emerging therapies could improve treatment.
Current Mesothelioma Trial
- Clinical Trial 24081: A Phase 1 study of SynKIR-110, an investigational cellular therapy using genetically modified T cells, for people with mesothelin-expressing advanced cancers, including mesothelioma.
Moffitt’s Mesothelioma Research and Treatment Program currently offers studies involving immunotherapy, gene therapy, targeted therapies, minimally invasive or robotic surgery and heated chemotherapy. Moffitt also offers many early-phase studies for thoracic and solid tumors, evaluating immune-based therapies, targeted drugs and other emerging treatments. Participation depends on factors such as diagnosis, tumor characteristics, previous treatment and overall health.
Why Choose Dr. Shafique for Pleural Mesothelioma?
Dr. Shafique treats pleural mesothelioma as part of his thoracic oncology practice at Moffitt Cancer Center. His background in medical oncology is relevant for patients considering chemotherapy, immunotherapy or clinical trials.
His work in immuno-oncology and early-phase clinical research connects his practice with efforts to evaluate new cancer treatments. Patients may want to discuss whether any of these investigational therapies or clinical trials fit their diagnosis and treatment goals.
Dr. Shafique sees patients at Moffitt at Speros in Land O’ Lakes, Florida. The facility offers medical oncology clinics, infusion services, diagnostic imaging and other outpatient cancer services.
Publications of Dr. Shafique
- Shafique, M. et al. (2026, August 4). ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin. Retrieved from https://aacrjournals.org/mct/article-abstract/25/8/1393/787067/ISL1-A-Novel-Neuroendocrine-Subtype-in-Small-Cell?redirectedFrom=fulltext
- Shafique, M. et al. (2026, March). Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use. Retrieved from https://www.clinical-lung-cancer.com/article/S1525-7304(25)00326-2/abstract
- Shafique, M. et al. (2025, October 4). Validation of the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to Facilitate Implementation in Research and Clinical Care. Retrieved from https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70102
- Shafique, M. et al. (2024, February). Phase I Study of Peposertib and Avelumab With or Without Palliative Radiotherapy in Patients With Advanced Solid Tumors. Retrieved from https://www.esmoopen.com/article/S2059-7029(23)01458-8/fulltext
- Shafique, M. et al. (2023, September 25). Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis. Retrieved from https://www.jcancer.org/v14p3169.htm